Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients

Clinical Infectious Diseases

Volumn 26, Issue 3, 1998, Pages 596-600

  Keay, Susan ^a   Oldach, David ^b   Wiland, Ann ^b   Klassen, David ^b   Schweitzer, Eugene ^b   Abruzzo, Lynne V ^b   Kumar, Dhruv ^b   Bartlett, Stephen ^b  

^a Baltimore VA Healthcare System   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DOSE RESPONSE; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0031967928     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514579     Document Type: Article

References (12)

1. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987;5:1673.
2. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552.
3. Swerdlow SH. Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology 1992;20:373.
4. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988;25:365.
5. Yousem SA, Randhawa P, Locker J, et al. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft. Hum Pathol 1989;20:361.
6. Lumbreras C, Femandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreas transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995;20:514.
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723.
8. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993:56:88.
9. Reyes CV, Jensen JA, Chinoy M. Pulmonary lymphoma in cardiac transplant patients treated with OKT3 for rejection: diagnosis by fine-needle aspiration. Diagn Cytopathol 1995;12:32.
10. Ho M, Miller G, Atchinson RW, et al. Epstein-Barr virus infections and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985:152:876.
11. Davis CL, Harrison KL, McVicar JP, et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995;9:53.
12. Starzl TE, Nalesnik MA, Porter KA, et al. Reversability of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984;1:583.